Exelixis, Inc. or Opthea Limited: Who Invests More in Innovation?

Exelixis vs. Opthea: A Decade of R&D Investment

__timestamp	Exelixis, Inc.	Opthea Limited
Wednesday, January 1, 2014	189101000	3401685
Thursday, January 1, 2015	96351000	4284228
Friday, January 1, 2016	95967000	3581295
Sunday, January 1, 2017	112171000	4838300
Monday, January 1, 2018	182257000	24891534
Tuesday, January 1, 2019	336964000	31347891
Wednesday, January 1, 2020	547851000	17480747
Friday, January 1, 2021	693716000	34710152
Saturday, January 1, 2022	891813000	108459978
Sunday, January 1, 2023	1044071000	181563523
Monday, January 1, 2024	910408000	176326321

Unveiling the hidden dimensions of data

Innovation Investment: Exelixis, Inc. vs. Opthea Limited

In the competitive world of biotechnology, innovation is key. Exelixis, Inc. and Opthea Limited are two companies that have consistently invested in research and development (R&D) to drive their growth. From 2014 to 2023, Exelixis, Inc. has shown a remarkable commitment to innovation, with R&D expenses increasing by over 450%. In contrast, Opthea Limited's R&D spending, while growing, has been more modest, with a 530% increase over the same period.

Exelixis, Inc. reached its peak R&D investment in 2023, spending nearly 1.04 billion dollars, a significant leap from its 2014 expenditure. Opthea Limited, on the other hand, saw its highest R&D spending in 2023 as well, with approximately 182 million dollars. This data highlights the strategic focus of both companies on innovation, albeit at different scales.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025